2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1710

Enthesitis in Psoriatic Arthritis: Incidence, Prevalence and Characteristics

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1233

Epidemiology of GCA in Bergen (Western Norway) 1972-2012

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1235

Epidemiology of Kikuchi-Fujimoto Disease in Martinique and Characteristics in an Afro-Caribbean Population: Close Relation with Lupus

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1234

Epidemiology of Sarcoidosis 1976-2013: A Population-Based Study

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1863

Epigenetic Changes in SLE Implicate Enhancers As a Force in Pathologic Cell Behavior

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1373

Epigenetic Mechanisms Contribute to the Lack of LPS-Induced Tolerance in Rheumatoid Arthritis Synovial Fibroblasts

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1624

Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis. Alterations Related to Cardiovascular Disease and Endothelial Dysfunction

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1262

Epigenome-Wide DNA Methylation Patterns Associated with Fatigue in Primary Sjögren’s Syndrome

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1683

Epithelial Changes in Response to Tocilizumab Combined with Methotrexate in Rheumatoid Arthritis: Evaluated on Circulating Fragments of Type IV Collagen

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1108

Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor

B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

9:00AM-11:00AM: Abstract Number: 1807

Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1228

Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1506

EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1296

Evaluating Inter-Rater Reliability in Joint Count to Promote Quality and Trust in a Clinical Arthritis Care Team

Health Services Research Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 1657

Evaluation of Bone and Joint Proteins for Prognostic Association with Radiographic Progression and Disease Activity in Methotrexate Inadequate Responder Rheumatoid Arthritis Patients in a Sarilumab Phase 3 Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].